Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and p53 in non-Hodgkin's lymphomas

Leukemia and Lymphoma

Volumn 30, Issue 5-6, 1998, Pages 625-636

  Korkolopoulou, P ^b,c   Angelopoulou, M K ^a   Kontopidou, F ^a   Tsengas, A ^a   Patsouris, E ^a   Kittas, Ch ^a   Pangalis, G A ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c NONE   (Greece)

Author keywords

AgNoRs; Non Hodgkin's lymphomas; p53; PCNA

Indexed keywords

CYCLINE; ONCOPROTEIN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME NOR; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TISSUE SECTION;

EID: 0031850168     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057575     Document Type: Article

References (52)

1. Armitage, J. O. (1993). Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
2. Coiffier, B., Gisselbrecht, C., Vose, J. M., Tilly, H., Herbrecht, R., Bosly, A. and Armitage, J. O. (1991). For the 'groupe d' Etudes des lymphomes aggressifs.' Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. Journal of Clinical Oncology, 9, 211-219.
3. Hanby, A. M., Hall, P. A., Rooney, N., Dennis, P., James, P., Richman, P., Buk, S., Levison, D. A. and Gregory, W. M. (1992). An inter-observer and intra-observer variability study on the diagnosis of lymph node biopsy specimens. European Journal of Cancer, 28, 1858-1862.
4. Celis, J. E. and Celis, A. (1985). Cell cycle dependent variations in the distribution of the nuclear protein cyclin/proliferating cell nuclear antigen in cultured cells: subdivision of the S phase. Proceedings of the National Academy of Science USA, 82, 3262-3266.
5. Czader, M., Porwit, A., Tani, E., Ost, A., Mazur, J. and Auer, G. (1995). DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non Hodgkin's lymphomas. Modern Pathology, 8, 51-58.
6. Pich, A., Ponti, R., Valente, G., Chiusa, L., Geuna, M., Novero, D. and Palestro, G. (1994). MIB-1, Ki 67 and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. Journal of Clinical Pathology, 47, 18-22.
7. Woods, A. L., Hall, P. A., Shepherd, N. A., Hanby, A. M., Waseem, N. H., Lane, D. P. and Levison, D. A. (1991). The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology, 19:21-27.
8. Garrido, M. C., Jones, M., Brown, D. C., Gatter, K. C. and Mason, D. Y. (1992). Monoclonal antibody PC10. Assessment of its potential value as a clinical marker in lymphoproliferative disease. Diagnostic Oncology, 2, 197-202.
9. Korkolopoulou, P., Patsouris, E., Pangalis, G., Tsenga, A., Elemenoglou, J., Thomas-Tsangli, E., Spandidos, D. and Kittas, C. (1993). A comparative assessment of proliferating cell nuclear antigen, c-myc p62 and nucleolar organizer region staining in non-Hodgkin's lymphomas. Human Pathology, 24, 371-377.
10. Schmidt, F. C., Rabenhorst, S. H., Maeda, S. A., Colturato, V. and Melo, L. N. (1996). Estimation of growth fraction in fine needle aspirates from non-Hodgkin's lymphomas using antiproliferating cell nuclear antigen: correlation with the Kiel classification. Acta Cytologica, 40, 199-204.
11. Crocker, J. (1989). Review: Proliferation indices in malignant lymphomas. Clinical and Experimental Immunology, 77, 299-308.
12. Crocker, J. and Nar, P. (1987). Nucleolar organiser regions in lymphomas. Journal of Pathology, 151, 111-118.
13. Crocker, J., Macartney, J. C. and Smith, P. J. (1988). Correlation between DNA flow cytometric and nucleolar organizer region data in non-Hodgkin's lymphomas. Journal of Pathology, 154, 151-156.
14. Vogelstein, B. and Kinzler, K. W. (1992). p53 function and dysfunction. Cell, 70, 523-526.
15. Xiong, P., Hannon, G., Zhang, H., Casso, D., Kohayashi, R. and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
16. Nigro, J. M., Baker, S. J., Presinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S. and Devilee, P. (1989). Mutations in the p53 gene occur in diverse human tumor types. Nature, 342, 705-708.
17. Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A. L. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675-679.
18. Lee, K. A., Finnegan, M. C. M., Sheridan, E., Hancock, B. W., Goepel, J. R., Royds, J. and Goyns, M. H. (1994). Analysis of the p53 gene, its expression and protein stabilization in non-Hodgkin's lymphomas. Annals of Oncology, 5(Suppl), S85-S88.
19. Piris, M. A., Villuendas, R., Martinez, J. C., Sanchez-Beato, M., Orradre, J. L., Mateo, M. S. and Martinez, P. (1994), p53 expression in non-Hodgkin's lymphomas: A marker of p53 inactivation. Leukemia and Lymphoma, 17, 35-42.
20. Villuendas, R., Piris, M. A., Algara, P., Sanchez-Beato, M., Sanchez-Verde, L., Martinez, J. C., Orradre, J. L., Garcia, P., Lopez, C. and Martinez, P. (1993). The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood, 82, 3151-3156.
21. National Cancer Institute (1982). Sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer, 49, 2112-2135.
22. Harris, N. L., Jaffe, E.S., Stein, H., Banks, P. M., Chan, J. K. C., Cleary, M. L., Delsol, G., De Worf-Peeters, C., Fallini, B., Gatter, K. C., Grogan, T. M., Isaacson, P. G., Knowles, D. M., Mason, D. Y., Muller-Hermelink, H. K., Pileri, S. A., Piris, M. A., Ralfkiaer, E. and Warnke, R. A. (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
23. Vojtesek, B., Bartek, J., Midgley, C. A. and Lane, D. P. (1992). An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. Journal of Immunology Methods, 151, 237-244.
24. Swerdlow, S. H., Westerman, C. D., Pelstring, R. J., Saboorian, H. and Williams, M. E. (1993). Growth fraction in centrocytic and follicular center cell lymphomas. Assessment in paraffin sections with a proliferating cell nuclear antigen antibody and morphometric correlates. Human Pathology, 24, 540-546.
25. Munck-Wikland, E., Edstrom, S., Jungmark, E., Kuylenstierna, R., Lindholm, J. and Auer, G. (1994). Nuclear DNA content, proliferating -cell nuclear antigen (PCNA) and P53immunostaining in predicting progression of laryngeal cancer in situ lesions. International Journal of Cancer, 56, 95-99.
26. Sanders, C. A., Yano, T., Clark, H. M., Harris, C., Longo, D. L., Jaffe, S. E. and Raffeld, M. (1993). P53 mutation is associated with progression in follicular lymphomas. Blood, 82, 1994-2004.
27. Kaplan, E. L. and Meier, P. (1958). Non-parametric estimation from incomplete observations. Journal of American Statisticians Association, 53, 457-481.
28. Lane, D. P. (1993). A death in the life of p53. Nature, 362, 786-787.
29. Weiss, L. M., Strickler, J. G., Medeiros, L. J., Gerdes, J., Stein, H. and Warnke, R. A. (1987). Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Human Pathology, 18, 1155-1159.
30. Doglioni, C., Pelosio, P., Mombello, A., Scarpa, A. and Chilosi, M. (1991). Immunohistochemical evidence of abnormal expression of the anti-oncogene encoded p53 phosphoprotein in Hodgin's disease and CD30+ anaplastic lymphomas. Haematological Pathology, 5, 67-73.
31. Korkolopoulou, P., Oates, J., Kittas, C. and Crocker, J. (1994). p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. Journal of Clinical Pathology, 47, 9-14.
32. Pezzela, F., Morrison, H., Jones, M., Gatter, K. C., Lane, D., Harris, A. L. and Mason, D. Y. (1993). Immunohistochemical detection of p53 and blc-2 proteins in non-Hodgkin's lymphoma. Histopathology, 22, 39-44.
33. Said, J. W., Barrera, R., Shintaku, P. I., Nakamura, H. and Koeffler, P. H. (1992). Immunohistochemical analysis of p53 expression in malignant lymphomas. American Journal of Pathology, 141, 1343-1348.
34. Soini, Y., Paakko, P., Alavaikko, M. and Vahakangas, K. (1992). p53 expression in lymphatic malignancies. Journal of Clinical Pathology, 45, 1011-1014.
35. Villuendas, R., Piris, M. A., Orrandre, J. L., Mollejo, M., Algara, P., Sanchez, L., Martinez, J. C. and Martinez, P. (1992). p53 protein expression in lymphomas and reactive lymphoid tissue. Journal of Pathology, 166, 235-241.
36. Hall, P. A., Richards, M. A., Gregory, W. M., d' Ardenne, A. J., Lister, T. A. and Stansfeld, A. G. (1988). The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphomas. Journal of Pathology, 154, 223-235.
37. Razumovic-Jakic, J., Petrovecki, M. and Dominis, M. (1995). AgNORs predictive value of prognosis in non-Hodgkin's lymphoma according to the Kiel classification. Modern Pathology, 8, 143-149.
38. Hernandez, L., Fest, T., Cazorla, M., Teruya-Feldstein, J., Bosch, F., Peinado, M. A., Piris, M. A., Montserrat, E., Cardesa, A., Jaffe, E. S., Campo, E. and Raffold, M. (1996). p53 gene mutations and protein over-expression are associated with aggressive variants of mantle cell lymphomas. Blood, 87, 3351-3359.
39. Lo Coco, F., Gaidano, G., Louie, D., Offit, K., Chaganti, R. S. K. and Dalla-Favera, R. (1993). p53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82, 2289-2295.
40. Nakamura, S., Akazawa, K., Kinukawa, N., Yao, T. and Tsuneyoshi, M. (1996). Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Human Pathology, 27, 225-233.
41. Ichikawa, A., Hotta, T., Tagaki, N., Tsushita, K., Kinoshita, T., Nagai, H., Murakami, Y., Hayashi, K. and Saito, H. (1992). Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood, 79, 2701-2707.
42. Piris, M. A., Pezzella, F., Montero-Martinez, J. C., Orradre, J. L., Villutendas, R., Sanchez-Beato, M., Cuena, R., Cruz, M. A., Martinez, B., Garrido, M. C., Gatter, K., Aiello, A., Delia, D., Giardini, R. and Rilke, F. (1994). P53 and bcl-2 expression in high grade B-cell lymphomas: Correlation with survival time. British Journal of Cancer, 69, 337-341.
43. Deb, S., Jackson, C. T., Suler, M. A. and Martin, D. W. (1992). Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. Journal of Virology, 66, 6164-6170.
44. Reich, N. C. and Levine, A. J. (1984). Growth regulation of a cellular tumour antigen p53 in non-transformed cells. Nature, 308, 199-201.
45. Gregory, W. M. (1992). Cell proliferation and the principles of cancer therapy. In: Hall, P.A., Levison, P.A. and Wright, N.A. (eds.) Assessment of cell proliferation in clinical practice (Springer Verlag, Berlin) pp. 193-205.
46. Wooldridge, T. N., Grierson, H. L., Weisenburger, D. D., Armitage, J. O., Sanger, W. G., Collins, M. M., Pierson, J. L., Pauza, M. E., Fordyce, R. and Purtilo, D. T. (1988). Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma. Cancer Research, 48, 6608-13.
47. McCormick, D. and Hall, P. A. (1992). The complexities of proliferating cell nuclear antigen. Histopathology, 21, 591-594.
48. Cabanillas, F., Pathak, S., Grant, G., Hagemeister, F. B., McLaughlin, P., Swan, F., Rodriguez, M. A., Trujillo, J., Cork, A., Butler, J. J., Katz, R., Bourne, S. and Freireich, E. J. (1989). Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. American Journal of Medicine, 87, 167-172.
49. Levine, E. G., Arthur, D. C., Frizzera, G., Peterson, B. A., Hurd, D. D. and Bloomfield, C. D. (1988). Cytogenetic abnormalities predict clinical outcome in non-Hodgkin's lymphoma. Annals of Internal Medicine, 108, 14-20.
50. Rodriguez, M. A., Ford, R. J., Goodaore, A., Selvanayagan, P., Cabanillas, F. and Deisseroth, A. B. (1991). Chromosome 17p and p53 changes in lymphoma. British Journal of Haematology, 79, 575-582.
51. Schouten, H. C., Sanger, W. G., Weisenburger, D. D., Anderson, J. and Armitage, J. O. (1990). Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics and treatment outcome. Blood, 75, 1841-1847.
52. Chin, K. V., Ueda, K., Pastan, I. and Gottesman, M. M. (1992). Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459-462.